NCT04083612View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Psoriasis Vulgaris
Interventions
PROCEDURE

Venapuncture

Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab

OTHER

Patient questionnaires

The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.

Trial Locations (7)

3000

UZ Hospital, Leuven

8000

AZ Sint-Jan, Bruges

8820

AZ Delta Rembert, Torhout

9000

AZ Maria Middelares, Ghent

AZ Sint-Lucas, Ghent

University Hospital of Ghent, Ghent

9990

Private Practice Dermatology, Maldegem

All Listed Sponsors
collaborator

KU Leuven

OTHER

collaborator

University Ghent

OTHER

lead

University Hospital, Ghent

OTHER

NCT04083612 - Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients | Biotech Hunter | Biotech Hunter